Pioneering Botanical Therapies for Inflammatory and Neurological Diseases

Investor Summary | 2024

Pioneers in Botanical Therapeutics

Canurta Day Video Series Email Image.jpg

Founded in 2021, Canurta Therapeutics develops botanically derived therapies for inflammatory and neurological diseases. Focused on rare polyphenols like cannflavins, we aim to deliver safe, effective treatments for conditions like ALS. Our lead candidate, CNR-401, leverages cutting-edge research and patented technologies, redefining neurodegenerative care.

Innovating Neurodegenerative Care with Nature

Harnessing Nature's Rarest Polyphenols

Cannflavins A (CFA) & B (CFB) are rare cannabis-derived polyphenols with potent anti-inflammatory and neuroprotective effects. Preclinical studies show they’re 30 times more effective and safer than Aspirin, targeting key proinflammatory enzymes (mPGES-1, 5-LO) and regulating neuroprotective enzymes like MAGL and FAAH. These compounds offer a groundbreaking approach to treating chronic inflammation and neurodegeneration.

AI-Driven Drug Development

Canurta’s PolyKye™ platform maximizes bioactive compounds for multi-target therapies. By integrating AI for drug optimization and bioinformatics for accelerated development, we bring these rare compounds to market faster. Our blockchain-enabled supply chain ensures CMC compliance, transparency, and scalability, setting new standards for efficiency and regulatory alignment.

Milestones and Growth

$10M

Raised in capital and non-dilutive funding to drive research, expansion, and innovation.

23

Filed patents in 7 major markets, covering novel extraction, biosynthesis, and activation production methods, therapeutic compositions, and AI-driven drug discovery.

11

Expert team members with a world-class advisory board, including key members from GW Pharma.

Neurodegenerative Complexity

By 2050, the number of people living with neurodegenerative diseases is expected to increase by nearly 60%.

Chronic Inflammation

Neuroinflammation fuels diseases like ALS and Alzheimer’s. Reducing it is critical to slowing disease progression.

Complex Dynamics

Neurodegenerative diseases progress quickly, requiring therapies that address multiple disease pathways simultaneously.

Treatment Limitations

Current therapies provide limited relief and neuroprotection, often with side effects, highlighting the need for safer solutions.

Lead Candidate CNR-401

CNR-401 optimizes cannabinoids with CFA and terpenoids to alleviate symptoms, enhance quality of life, and provide neuroprotection in ALS and related neurodegenerative diseases like Alzheimer's and Frontotemporal Dementia.

CNR-401: Neurodegenerative Care | Canurta Therapeutics

CBD

Other Minor Cannabinoids

Terpenoids

CFA

Innovative Composition: A synergistic blend of CBD, CFA, and terpenoids enhances multi-target efficacy.

Safety Profile: Minimal side effects and low-risk dosing, supported by Sativex, a cannabinoid-based drug approved in 30+ countries for ALS symptoms.

Lipid-Based Formulation: Designed for peak bioavailability and easy oral administration.

Scalable & Sustainable: GMP-compliant and utilizes upcycled plant materials.

Regulatory Alignment: FDA rescheduling, the 2018 Farm Bill, and Botanical Drug Guidance offer a clear path, while global cannabis programs expand access.

Mechanisms of Action

CNR-401's unique formulation targets key processes like inflammation, neuroprotection, and muscle control, offering therapeutic benefits across multiple pathways to address the complex mechanisms of diseases like ALS.

Vast Market Potential

The neurodegenerative disease market is rapidly expanding, providing a prime opportunity for CNR-401 to drive innovation. Consistent growth and rising prevelance fuel strong investment prospects.

$969M ALS Market: Projected by 2028.

Orphan Designation Exclusivity: 7 years in the US and 10 in the EU, granting market dominance.

Only Two FDA-Approved Botanical Drugs: Highlighting an untapped market.

Pipeline-in-a-product: Potential for blockbuster status across multiple conditions.

Current Treatment Limitations

Radicava (Edaravone)

$185,000/year

Limited to neuroprotection
Modest efficacy
No symptom relief

Riluzole

$5,403/year

Limited to neuroprotection
Modest efficacy
No symptom relief

Sativex

$7,822/year

Limited to spasticity and pain
No neuroprotection
Not approved in ALS

Go-to-Market Strategy

Affordable Pricing

CNR-401 offers comprehensive ALS symptom relief and neuroprotection at a fraction of the cost of Edaravone, with broader benefits than Riluzole and a modest premium over Sativex.

Minimum $19,555/year

Early Market Entry

CNR-401 will enter Germany with general health claims, supported by CDMOs and near-100% reimbursement, gathering Real-World Evidence to fuel expansion into broader neurodegenerative markets.

Medical Cannabis in Germany

First-in-Human Trials

Simultaneous IITs in the U.S. will generate data to inform future Registration trials, supporting global expansion and reimbursement pathways.

Preliminary Data to Guide Trials

Revenue Projections

Early revenue targets are hit in 2025 with $977K from ALS patients. This scales to $31.7M by 2026 as the market expands. Profitability is reached in 2027, and by 2028, revenue grows to $231.1M, with ongoing expansion into key global markets.

We are raising $5M in our Pre-Seed round

Early investors gain a first-mover advantage in the rapidly growing neurodegenerative market, supported by proprietary cannabis therapies and de-risked through government-backed funding.

First-in-Human Study: Utilizing early data to drive success in the Registration Trial.

Early Market Entry: Launching in Germany’s medical cannabis program to gather real-world evidence.

CMC and Facility Completion: Advancing CMC work and completing a state-of-the-art facility to scale production and fuel growth.

Public Listing: Targeting a 2025 TSV-X public listing.

Mapping the Journey to Botanical Drug Approval

Investigator Initiated Trials (2026)

Early-stage clinical data gathered from IITs, supporting therapeutic potential and accelerating regulatory submissions.

Registration Trial (2028)

Large-scale trials begin, leading to conditional approval under fast-track approval, setting the stage for global regulatory submissions and market entry.

Initial Market Entry (2025)

Early revenue targets are hit in 2025 with $977K from ALS patients. This scales to $31.7M by 2026 as the market expands.

Orphan Drug Designation (2027)

ODD approval solidifies market exclusivity and fast-tracks CNR-401's path to ALS treatment.

Phase IV Confirmatory Trials (2030)

Co-developed confirmatory trials enable broader global market access under the 505(b)(2) pathway, leading to full product approval and widespread use.

Lucrative Exit Potential

Canurta Therapeutics

Credible Science Team

Robust Clinical Pipeline

Blockbuster Potential

Novel Cannabis Molecules

AI & Bioinformatics Platform

GW Pharmaceuticals

Credible Science Team

Robust Clinical Pipeline

Blockbuster Potential

Exit

11.3B

(2030 +/- 3 years)

7.2B (2021)

Potential ROI at Exit
Average Return	90.16x
PIPE 3	12.2x (916.6M)
PIPE 2	48.9x (1.46B)
PIPE 1	195.56x (997M)
RTO Warrants	176x ($667M)
Pre-Seed Equity	189.8x (949M)

Partnered for Success

Canurta expands its offerings, reaches new markets, and taps into specialized expertise through collaborations with innovative partners across industry, academia, and government.